secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001628280-23-015205
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q1 IBSRELA sales $11.4M, net loss $26.8M; XPHOZAH NDA resubmitted
-------------------------------------------------------------------------

- IBSRELA net product sales $11.4M in Q1 2023, up from $0.5M in Q1 2022.
- Net loss $26.8M ($0.13/share) vs $28.1M ($0.21/share) in prior-year period.
- Cash and investments $130.4M as of March 31, 2023; raised $51.9M from ATM offering.
- XPHOZAH NDA resubmitted to FDA on April 17, 2023 for phosphate control in CKD patients on dialysis.
- Licensed TGR5 agonist portfolio to METiS Therapeutics for $750K upfront + up to $243M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/0001628280-23-015205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023015205/ardx-20230503.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer